Avoro Capital Advisors LLC
Q1 2020 13F-HR Holdings
Net value change ($000)
-442,993
(-13.0%)
New positions
12
Sold out positions
0
Turnover %
10.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2019
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| XLRN | 77,288 | NEW |
| PTCT | 53,532 | NEW |
| Deciphera Pharmaceuticals, Inc. | 51,220 | 164.6% |
| RLMD | 39,227 | NEW |
| AVDL | 34,663 | NEW |
| Sage Therapeutics, Inc. | 28,720 | NEW |
| IOVA | 25,422 | 10.4% |
| AUPH | 25,030 | NEW |
| KPTI | 21,367 | 18.9% |
| Trillium Therapeutics Inc. | 19,998 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| IMMUNOMEDICS INC | -188,160 | -36.3% |
| Mirati Therapeutics, Inc. | -179,994 | -36.3% |
| SRPT | -72,065 | -31.7% |
| ASND | -58,225 | -22.4% |
| CONSTELLATION PHARMACEUTICALS INC | -57,232 | -33.3% |
| MyoKardia, Inc. | -44,970 | -40.1% |
| QURE | -43,529 | -35.7% |
| Athenex, Inc. | -42,609 | -53.0% |
| ZOGENIX, INC. | -35,016 | -33.6% |
| AMARIN CORP PLC | -32,736 | -80.4% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
3,135
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|